Breakingviews

Reuters Breakingviews is the financial commentary division of Reuters News. We offer insightful analysis on important financial issues as they develop across the United States, Europe, the Middle East, and Asia every day. Our global team, consisting of around 30 journalists located in key cities like New York, London, and Hong Kong, provides real-time expert commentary. Our articles are accessible to finance professionals through platforms like Refinitiv's Eikon, as well as on breakingviews.com and our mobile apps for both iPhone and Android. Our content reaches a wide audience, including asset managers, corporate leaders, private equity investors, investment bankers, and attorneys. Additionally, we share select pieces on reuters.com and collaborate with prominent print and digital partners worldwide.

Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1252670

United Kingdom

#236191

Finance/Investing

#1787

Traffic sources

Monthly visitors

Articles

Fed chair’s foes form a risky new Team Transitory

1 day ago | breakingviews.com | Gabriel Rubin

U.S. President Donald Trump arrives in the Rose Garden to announce Jerome Powell as his nominee to become chairman of the U.S. Federal Reserve at the White House in Washington, U.S., November 2, 2017. REUTERS/Carlos Barria/File PhotoJay Powell, burned by stickier-than-expected inflation, is shy of letting haphazard policy singe him again.
Muddled US meddling grinds factory gears

3 days ago | breakingviews.com | Gabriel Rubin

WASHINGTON, June 25 (Reuters Breakingviews) - Trying to reshape the U.S. economy around manufacturing is hard enough without helter-skelter industrial policy. Cancelled subsidies, shredded contracts and unpredictable tariffs should be partly countervailed by tax and regulation breaks. On balance, however, President Donald Trump’s highly personal and protectionist approach to investment and trade adds up to a losing proposition.
US housing slump redrafts homebuilders’ blueprint

3 days ago | breakingviews.com | Sebastian Pellejero

A U.S. flag decorates a for-sale sign at a home in the Capitol Hill neighborhood of Washington, August 21, 2012. President Barack Obama said on Monday the U.S. housing market was "beginning to tick up" but was still not where it needs to be. REUTERS/Jonathan Ernst (UNITED STATES - Tags: BUSINESS REAL ESTATE)Sales of existing homes are at a 16-year low, inventories are rising, yet affordability is stretched.
Iran strike intensifies Trump counterparty risk

4 days ago | breakingviews.com | Gabriel Rubin

Sign up now to keep reading Reuters BreakingviewsReuters Breakingviews delivers agenda-setting financial insight in real time, keeping you informed around the clock. If you are a subscriber, please sign in to read this column. Breakingviews offers concise and compelling views on the biggest global stories. We respond quickly to major events, providing insight at speed. Our columnists crunch numbers and tap trusted sources to come up with well-informed insights.
Holcim’s post-split boost hints at a rosier Europe

4 days ago | breakingviews.com | Aimee Donnellan

Rail carriages are pictured at the Siggenthal plant of cement maker Holcim in Wurenlingen near Zurich, Switzerland, June 27, 2024. REUTERS/Denis Balibouse/File PhotoShares in the Swiss cement giant’s $29 bln US unit fell, as those in its rump soared. When Holcim unveiled its spinoff in 2024, the European arm looked like a backwater. Investors’ enthusiasm reveals how the Trump administration’s polices have shifted the transatlantic dynamics.
Vaping bust kindles Big Tobacco’s comeback

1 week ago | breakingviews.com | Sebastian Pellejero

Sign up now to keep reading Reuters BreakingviewsReuters Breakingviews delivers agenda-setting financial insight in real time, keeping you informed around the clock. If you are a subscriber, please sign in to read this column. Breakingviews offers concise and compelling views on the biggest global stories. We respond quickly to major events, providing insight at speed. Our columnists crunch numbers and tap trusted sources to come up with well-informed insights.
Renault exit could grease Nissan’s turnaround

1 week ago | breakingviews.com | Katrina Hamlin

Sign up now to keep reading Reuters BreakingviewsReuters Breakingviews delivers agenda-setting financial insight in real time, keeping you informed around the clock. If you are a subscriber, please sign in to read this column. Breakingviews offers concise and compelling views on the biggest global stories. We respond quickly to major events, providing insight at speed. Our columnists crunch numbers and tap trusted sources to come up with well-informed insights.
China may win more than EU from auto tariff truce

1 week ago | breakingviews.com | Neil Unmack |Katrina Hamlin

Sign up now to keep reading Reuters BreakingviewsReuters Breakingviews delivers agenda-setting financial insight in real time, keeping you informed around the clock. If you are a subscriber, please sign in to read this column. Breakingviews offers concise and compelling views on the biggest global stories. We respond quickly to major events, providing insight at speed. Our columnists crunch numbers and tap trusted sources to come up with well-informed insights.
UK M&A bargain-hunters help fix London discount

1 week ago | breakingviews.com | Yawen Chen

Sign up now to keep reading Reuters BreakingviewsReuters Breakingviews delivers agenda-setting financial insight in real time, keeping you informed around the clock. If you are a subscriber, please sign in to read this column. Breakingviews offers concise and compelling views on the biggest global stories. We respond quickly to major events, providing insight at speed. Our columnists crunch numbers and tap trusted sources to come up with well-informed insights.
Biotech nears cure for Chinese corporate epidemic

1 week ago | breakingviews.com | Jeffrey Goldfarb

NEW YORK, June 19 (Reuters Breakingviews) - Just as Covid lingers, so too does a protracted corporate battle over more than $10 billion earned trying to protect people from the deadly virus. A ruthless clash for control of Sinovac Bioscience, whose vaccine became one of the world’s biggest sellers, has left its stock untradeable on Nasdaq for more than six years.